14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Oct 02, 2026
BSLK vs VTAK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Oct 02, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Bolt Projects Holdings, Inc. (BSLK) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BSLK carries a Unified Composite Score of 41.2/100 (SELL) at $0.58 (N/M Forward P/E, -1179.5% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin).
Growth vs. Quality Trade-Off: VTAK earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. BSLK 41.2/100 SELL) and 0.19β · 76% Vol risk profile, whereas BSLK leads top-line expansion (+7300.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: BSLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.8); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BSLK vs VTAK Key Questions & Quantitative Answers
As of Oct 02, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Bolt Projects Holdings, Inc. (BSLK) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BSLK carries a Unified Composite Score of 41.2/100 (SELL) at $0.58 (N/M Forward P/E, -1179.5% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin). Growth vs. Quality Trade-Off: VTAK earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. BSLK 41.2/100 SELL) and 0.19β · 76% Vol risk profile, whereas BSLK leads top-line expansion (+7300.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BSLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.8); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BSLK leads the Growth & Scale pillar: BSLK posts +7300.0% YoY revenue growth and +0.0% YoY earnings growth on $3.1M TTM revenue (3.2% gross margin, -1179.5% operating margin), compared with VTAK at +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin). Across the 3-period historical trajectory (Q1 '25 to Q3 '25), BSLK cumulative revenue shifted N/A while VTAK shifted N/A. In operating R&D and SG&A reinvestment, BSLK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTAK.
BSLK and VTAK trade at balanced relative valuation multiples. BSLK trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BSLK (-4288.3% ROE) versus VTAK (-111.3% ROE) capital efficiency.
In options market volatility and institutional positioning, BSLK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.04β · 148% Vol realized risk). By comparison, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Oct 02, 2026. For educational research only; not investment advice.